Drugs Made In America Acquisition (DMIIR) Preferred Stock Liabilities (2025 - 2026)

Drugs Made In America Acquisition (DMIIR) has reported Preferred Stock Liabilities for 1 consecutive years, with $504.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Preferred Stock Liabilities changed N/A year-over-year to $504.9 million; the TTM figure through Dec 2025 stood at $504.9 million (changed N/A YoY), while the FY2025 annual figure was $504.9 million, changed N/A from the prior year.
• Preferred Stock Liabilities improved to $504.9 million in Q4 2025 per DMIIR's latest filing, from $500.1 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $504.9 million in Q4 2025 and bottomed at $500.1 million in Q3 2025.